Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Artemether-lumefantrine plus atovaquone-proguanil tri-therapy for uncomplicated malaria in African children
PACTR202201797112873Phase 3Completed
- Sponsor
- Kwame Nkrumah University of Science and Technology
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial of artemether, lumefantrine, atovaquone and proguanil in malaria and Falciparum malaria (PF) (2 arms), sponsored by Kwame Nkrumah University of Science and Technology. Started Oct 2021; status: completed.
02
Drugs
artemetherlumefantrineatovaquoneproguanil
03
Conditions
malariaFalciparum malaria (PF)
Beyond the preview
Go deeper on PACTR202201797112873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202201797112873.